RPG Life Sciences saw its shareholding structure shift as Clarus Trust increased its stake by 0.23% through open market purchases, bringing its total holding to 7.04%.

The acquisition, executed by Clarus Capital I, involved the purchase of 37,463 equity shares on September 25, 2026. This transaction triggered a disclosure under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, as the change in holding exceeded the mandatory 2% threshold from the previous disclosure date of April 20, 2026.

Stakeholding Details

The Clarus Trust, acting through its schemes including Clarus Capital I, II, and LVF variants, along with person acting in concert ClearEdge LLC, now holds a significant minority position in the pharmaceutical company. The shares acquired are fully paid equity shares with a face value of ₹8 each.

Regulatory Compliance

ChrysCapital Associates LLP, serving as the Investment Manager for the Trust, filed the necessary disclosures with both BSE Limited and the National Stock Exchange of India Limited. The filing confirms that the acquirer does not belong to the promoter or promoter group of RPG Life Sciences.

The total equity share capital of the company remains unchanged at ₹13,23,12,120, comprising 1,65,39,015 equity shares of ₹8 each. The diluted share capital figures are identical to the voting capital, indicating no outstanding convertible securities or warrants that would alter the voting power calculation.

RPG Life Sciences Limited subsidiary RPG Active Pharma Limited has approved a scheme of amalgamation of its wholly owned subsidiary, Actis Generics Private Limited, with itself.

The Board of Directors of RPG Active Pharma approved the proposal on September 25, 2026. The transaction is subject to approvals from the National Company Law Tribunal and shareholders. Since Actis is already a wholly owned subsidiary, no shares will be issued as consideration for the merger.

Strategic rationale and financial impact

The amalgamation aims to consolidate assets and liabilities into a single entity to streamline the corporate structure. Key benefits cited include cost savings through legal entity rationalization, elimination of duplicate expenses, and improved management oversight. The consolidation is expected to strengthen the balance sheet and net worth of RPG Active Pharma, potentially facilitating better terms with lenders.

The entities operate in complementary areas within the pharmaceutical value chain. Actis Generics engages in manufacturing pharmaceutical, medical chemicals, and botanical products. RPG Active Pharma focuses on manufacturing and marketing active pharmaceutical ingredients.

Financial details of merging entities

As of March 31, 2026, RPG Active Pharma reported a net worth of ₹34.75 crore. The company was incorporated on December 24, 2025, and did not record any revenue from operations in FY26. Actis Generics reported a net worth of ₹34.60 crore and revenue from operations of ₹45.96 crore during FY26.

Regulatory and shareholding implications

The transaction falls under Sections 230 to 232 of the Companies Act, 2013. Although the companies are related parties, the transaction does not attract Section 188 requirements per MCA General Circular No. 30/2014. Upon effectiveness, shares of Actis Generics held by RPG Active Pharma will stand cancelled. There will be no change in the shareholding pattern of RPG Life Sciences Limited.